MRI Predictors of Response to Tumor Treating Fields
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/20/2018 |
| Start Date: | December 1, 2018 |
| End Date: | December 31, 2023 |
| Contact: | Adel Guirguis, MD, MS |
| Email: | adg9003@nyp.org |
| Phone: | 718-780-3677 |
Imaging Biomarkers to Predict Responsiveness to Tumor Treating Fields in Patients With High Grade Glioma
Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment
with tumor treating fields using the Optune device as part of standard of care therapy. While
undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor
progression, but there are currently no means to predict which, or when, patients will
progress. The purpose of the current study is to prospectively analyze these MRI scans to
look for subtle imaging markers that can predict for future brain tumor progression while
undergoing tumor treating field therapy.
with tumor treating fields using the Optune device as part of standard of care therapy. While
undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor
progression, but there are currently no means to predict which, or when, patients will
progress. The purpose of the current study is to prospectively analyze these MRI scans to
look for subtle imaging markers that can predict for future brain tumor progression while
undergoing tumor treating field therapy.
The proposed trial involves the prospective collection of imaging data at standard clinical
time points before and during treatment with TTFields. All patients who are offered treatment
with TTFields will also be offered enrollment in this non-randomized, observational study.
Imaging data will include the standard battery of MRI sequences, which includes DWI and ADC
reconstruction. These data will be collected at standard time points and the proposed study
will not rely on any additional imaging or tests outside of the clinical standard of care.
time points before and during treatment with TTFields. All patients who are offered treatment
with TTFields will also be offered enrollment in this non-randomized, observational study.
Imaging data will include the standard battery of MRI sequences, which includes DWI and ADC
reconstruction. These data will be collected at standard time points and the proposed study
will not rely on any additional imaging or tests outside of the clinical standard of care.
Inclusion Criteria:
- Patients age 18 or older with newly diagnosed WHO grade IV glioblastoma or patients
with recurrent glioblastoma not previously treated with TTFields.
- Patients may have undergone surgical resection or biopsy.
- Residual tumor, absence of treatment with temozolomide or radiation therapy will not
be an exclusion criteria for the study.
Exclusion Criteria:
- Patients previously treated with TTFields will not be included in the study.
- Patients will also be excluded if they are undergoing active treatment with systemic
agents, including bevacizumab, during treatment with TTFields.
We found this trial at
1
site
263 7th Avenue
Brooklyn, New York 11215
Brooklyn, New York 11215
Principal Investigator: Theodore Yanagihara`, MD, PhD
Phone: 718-780-3677
Click here to add this to my saved trials
